Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. - Wikidata - awgldk - TriplyDB

Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis.

Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis.

http://www.wikidata.org/entity/Q33266259

about

FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome.SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling molecule expressed in prostate carcinomas Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis.A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.Molecular genetics of prostate cancer: new prospects for old challenges Molecular pathways and targets in prostate cancer A three-protein biomarker panel assessed in diagnostic tissue predicts death from prostate cancer for men with localized disease.Apoptosis, autophagy, necroptosis, and cancer metastasis PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis.Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer Loss of Wave1 gene defines a subtype of lethal prostate cancer Mouse models of advanced spontaneous metastasis for experimental therapeutics.Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility.Akt1 mediates prostate cancer cell microinvasion and chemotaxis to metastatic stimuli via integrin β₃ affinity modulation.Protein tyrosine phosphatases: new markers and targets in oncology?Personalized management in low-risk prostate cancer: the role of biomarkers.Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells Integrin signaling aberrations in prostate cancer.Recent developments in prostate cancer biomarker research: therapeutic implications.Disruption of prostate epithelial differentiation pathways and prostate cancer development.The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.Prognostic and predictive biomarkers in prostate cancer.PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients Expression and clinical significance of FAK, ILK, and PTEN in salivary adenoid cystic carcinoma.Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.Anticancer effect of deoxypodophyllotoxin induces apoptosis of human prostate cancer cells.PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer.Castration-resistant prostate cancer: targeted therapies and individualized treatment Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy Prostate Cancer - What's New?

P2860

Q27851411-9CF80885-4254-4008-B1CF-CD06A08E98ED Q28237131-E2B6282D-18AA-47B1-B8A3-7EEB0387B9AC Q28382812-D0D815C4-42EE-4FE9-81F5-2D7BE0DF9F0D Q28475546-6D2CE4E3-C60D-40E0-9F99-D4CAD1A90DC1 Q30595149-54480CE2-04D7-4887-BB05-82833113B9E6 Q33730212-EEF94AC0-7227-4450-868C-832ADE1B0D99 Q33789808-A239D885-3D2D-4DB9-811E-01C80894BA28 Q33936343-9C04B8A2-640A-4B6F-836B-B3A9A801FFE1 Q34127462-EB18691E-BC43-4B3F-8441-6139CA4A5920 Q34365632-0BFB6DAC-50C3-451C-98A0-FE46F4D1EA98 Q34998516-9BDC44B5-CB87-47E7-9E46-DCA01AC4C917 Q35128650-E81FEFE8-564A-476D-AE7C-FD237E2B6F97 Q35540013-7FA25F6F-9422-495F-A31C-E57B8AD343D9 Q35586422-19CD0ECB-9643-4E45-B084-9140245C5785 Q35764742-DFDA6B7E-C3D4-49EE-9582-0F79BF09E2CE Q35828579-8DAA0B40-3700-46FB-835F-EC671C7331D2 Q35966786-3656202F-3A51-46FD-A46A-FC04E5417522 Q35999379-326EDC4B-F6ED-4E34-BAF2-55C991150AFE Q36166788-ED4B8215-71B8-4C50-AF28-431B7F8A8462 Q36485213-FE7A2D28-FDC5-417D-A506-882F22B655CC Q36495701-397AD0A5-0254-4682-B268-556417DD948B Q36892504-A1A38AE4-B4AD-4626-BC9E-956AA2AD7CCA Q36959119-5B5DE2B6-11B3-472F-877A-2D2447465493 Q37016007-5BC8273F-7820-44A7-B329-2CC67E59FFDB Q37214332-A84EEE4C-7A4A-446E-B7B6-E85F0B4BCDDB Q37383459-F0B3C8EB-F218-4585-BF0A-F0A26C6D8B09 Q37437827-045A9B22-4CE3-4DEE-B4DD-48F31F9F9A76 Q37643449-756C35B6-CE25-47F1-B14C-BB69944546C5 Q37827186-90E66C13-F237-47C4-A119-5A06CAB0544B Q38160495-613DBFDF-0B25-461D-B8A3-125ACEAC0540 Q38370773-B6CD6EDC-4E8E-4D57-B714-4B6D47790946 Q38628081-8C41978B-E81B-4F2A-B1ED-75BA681ED6DC Q38738670-1BA928FA-6922-4973-9406-33BD91B9710F Q39237189-446D419E-F464-4759-A037-B5C23C2C36E8 Q39260908-F1EEF270-D61A-451E-BBE0-55655DDC88C5 Q39326181-62B8D663-E42C-4E1E-A1F1-1CB516C2957C Q39401816-1B79F6FB-381D-4D86-9628-3B839A32A2A4 Q39511732-8F5D6775-FC1D-49F7-8A74-7CF8076011D9 Q40740686-60A7919B-E4A0-45B9-8422-042DCBD27EDA Q41821945-5EBD4972-515F-467B-9706-79DD9DE6B4C8

P2860

Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis.

http://www.wikidata.org/entity/Q33266259

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Complete loss of PTEN expressi ...... or prostate cancer metastasis.

@ast

Complete loss of PTEN expressi ...... or prostate cancer metastasis.

@en

type

label

Complete loss of PTEN expressi ...... or prostate cancer metastasis.

@ast

Complete loss of PTEN expressi ...... or prostate cancer metastasis.

@en

prefLabel

Complete loss of PTEN expressi ...... or prostate cancer metastasis.

@ast

Complete loss of PTEN expressi ...... or prostate cancer metastasis.

@en

P1433

Q33266259-BE2E870C-0C39-4DDA-A830-7C10ECEC0B44

P1476

Q33266259-83961B66-37F4-4425-8CD4-6F64589A0EDA

P2093

Q33266259-42E09FCF-10B8-4840-A57E-E0F7854F56E7

Q33266259-90934865-7852-4E4B-B6DE-36DB2A18F032

Q33266259-936998A0-1493-4391-AF81-1EB2B005CD2C

Q33266259-94732E79-4BD7-42A1-B58D-A8AF70068758

Q33266259-A2EE4B34-5205-477D-9913-827BA92D7BFC

Q33266259-A6BE6372-6707-4B74-86BB-9CD3ABE61DDC

Q33266259-AB490B80-91D2-4F52-89FD-E65BA4992304

Q33266259-B853FC27-A18C-4633-ADEA-E48876E41DCA

Q33266259-EA022366-222A-4292-9D4D-509C5DD01215

P304

Q33266259-9E719123-B862-4BE8-8D2B-9AB9AD462228

P31

Q33266259-35398664-9EDF-400C-8C33-32D6C78ACFA6

P356

Q33266259-966C9BF2-306C-4ED0-B622-3BA161B22762

P433

Q33266259-2A55C82E-7C9C-472A-90E5-134C310621C1

P478

Q33266259-9B59FA51-D72C-4154-8237-F545FA7A445D

P50

Q33266259-6579270E-E7FC-43EF-B23A-7FBD3094F36F

P577

Q33266259-D10F7D70-EB2C-483A-8AF3-6B7AAD35A691

P5875

Q33266259-8DF3AA2E-72F7-4BC5-A2C5-587564C9F230

P698

Q33266259-4DEA46CB-B32C-41F9-93E1-BEFEA72B55FC

P356

P1433

International Journal of Cancer

P1476

Complete loss of PTEN expressi ...... or prostate cancer metastasis.

@en

P2093

Catherine Capesius

http://www.w3.org/2001/XMLSchema#string

Christiane Margue

http://www.w3.org/2001/XMLSchema#string

Gérard Grignard

http://www.w3.org/2001/XMLSchema#string

Martine Schmitz

http://www.w3.org/2001/XMLSchema#string

Michel Nathan

http://www.w3.org/2001/XMLSchema#string

Nelly Kieffer

http://www.w3.org/2001/XMLSchema#string

René Scheiden

http://www.w3.org/2001/XMLSchema#string

Sandro Giacchi

http://www.w3.org/2001/XMLSchema#string

Walter Dippel

http://www.w3.org/2001/XMLSchema#string

P304

1284-1292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.22359

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6637246

http://www.w3.org/2001/XMLSchema#string

P698

17163422

http://www.w3.org/2001/XMLSchema#string